<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
<p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - 免費報告) - Lifesci Capital 的股票研究人員在 2026 年第二季度的研究報告中發佈了對 Corbus Pharmaceuticals 的每股收益（EPS）預測，該報告於 5 月 13 日星期三發給客户和投資者。Lifesci Capital 分析師 O. Mccammon 預測該生物製藥公司本季度每股收益為（$1.24）。對 Corbus Pharmaceuticals 當前全年的共識預期為每股（$4.78）。Lifesci Capital 還發布了對 Corbus Pharmaceuticals 2026 年第四季度每股收益的預測為（$1.51）和 2026 財年的每股收益為（$5.07）。</p>
<p>獲取 <strong>Corbus Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾位分析師也對 CRBP 發佈了報告。華爾街禪在 4 月 25 日星期六的報告中將 Corbus Pharmaceuticals 的評級從 “強烈賣出” 上調至 “賣出”。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Corbus Pharmaceuticals 股票的 “賣出（d-）” 評級。Oppenheimer 在週三的報告中將 Corbus Pharmaceuticals 的目標價從 57.00 美元下調至 54.00 美元，並對該公司設定了 “跑贏大盤” 的評級。Jefferies Financial Group 在週二的報告中將 Corbus Pharmaceuticals 的目標價從 36.00 美元下調至 33.00 美元，並對該公司設定了 “買入” 評級。最後，Guggenheim 在週三的報告中重申了 “買入” 評級，並對 Corbus Pharmaceuticals 股票設定了 45.00 美元的目標價。一位股票研究分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，兩位分析師給予了賣出評級。根據 MarketBeat 的數據，Corbus Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 42.33 美元。</p>
<ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP 發出強烈買入信號</li>
</ul>
<p><strong>查看我們最新的 CRBP 股票報告</strong></p>
<h2>Corbus Pharmaceuticals 股價上漲 6.3%</h2>
<p>NASDAQ:CRBP 的股票在週四開盤價為 12.15 美元。Corbus Pharmaceuticals 的一年低點為 6.72 美元，一年高點為 20.56 美元。該公司的 50 日簡單移動平均線為 9.77 美元，200 日簡單移動平均線為 9.66 美元。該公司的市值為 2.1554 億美元，市盈率為-2.09，貝塔值為 2.68。</p>
<p>Corbus Pharmaceuticals (NASDAQ:CRBP - 獲取免費報告) 最近在 5 月 12 日星期二公佈了季度財報。該生物製藥公司報告的每股收益為（$1.23），超出共識預期的（$1.26）0.03 美元。</p>
<h2>對 Corbus Pharmaceuticals 的對沖基金看法</h2>
<p>機構投資者最近對該公司的持倉進行了調整。Assenagon Asset Management S.A. 在第四季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 120.2%。Assenagon Asset Management S.A. 現在擁有 187,956 股該生物製藥公司的股票，價值 1,530,000 美元，在此期間又購買了 102,609 股。Aberdeen Group plc 在第四季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 602.2%。Aberdeen Group plc 現在擁有 1,321,750 股該生物製藥公司的股票，價值 10,759,000 美元，在此期間又購買了 1,133,519 股。HighVista Strategies LLC 在第三季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 56.8%。HighVista Strategies LLC 現在擁有 118,027 股該生物製藥公司的股票，價值 1,493,000 美元，在此期間又購買了 42,735 股。Virtu Financial LLC 在第四季度收購了 Corbus Pharmaceuticals 的新股份，價值約 88,000 美元。最後，Engineers Gate Manager LP 在第四季度收購了 Corbus Pharmaceuticals 的新股份，價值約 140,000 美元。64.64% 的股票目前由機構投資者持有。</p>
<h2>Corbus Pharmaceuticals 主要新聞</h2>
<p>以下是本週影響 Corbus Pharmaceuticals 的主要新聞：</p>
<ul>
<li>積極情緒：Corbus 報告 2026 年第一季度每股收益為 <strong>($1.23)</strong>，超出共識預期 0.03 美元，表明本季度的結果略好於預期。</li>
<li>積極情緒：該公司表示已就 <strong>CRB-701</strong> 在頭頸部鱗狀細胞癌和宮頸癌的註冊路徑達成廣泛的 FDA 一致意見，這是朝着今年夏天進行註冊研究的重要監管步驟。</li>
<li>積極情緒：Corbus 完成了 <strong>CANYON-1</strong> 肥胖研究的入組，預計將在夏季發佈 16 周的頂線數據，增加了近期催化劑。</li>
<li>積極情緒：HC Wainwright 和 LifeSci Capital <strong>提高了 2026-2030 年的多項收益預期</strong>，反映出對公司長期收益軌跡的改善預期。</li>
<li>積極情緒：幾家券商維持了建設性的觀點，包括 <strong>Guggenheim 的買入評級</strong> 和 <strong>Oppenheimer 的跑贏大盤評級</strong>，顯示出分析師的持續信心。Corbus Pharmaceuticals 將參加即將舉行的投資者會議。</li>
<li>中性情緒：Corbus 將在紐約的即將舉行的投資者會議上進行演講，這可能會增加可見度，但本身並不會改變基本面。Corbus Pharmaceuticals 將參加即將舉行的投資者會議。</li>
<li>消極情緒：第一季度淨虧損擴大至約 <strong>2300 萬美元</strong>，運營費用增加，突顯出 Corbus 仍然是一家高燒錢的臨牀階段生物技術公司，尚未盈利。</li>
<li>消極情緒：Oppenheimer <strong>將其目標價</strong> 從 57 美元下調至 54 美元，儘管仍然看漲，但可能抑制了一些熱情。</li>
</ul>
<h2>關於 Corbus Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Corbus Pharmaceuticals Holdings, Inc 是一家臨牀階段的生物製藥公司，致力於開發和商業化針對罕見、危及生命的炎症和纖維化疾病的治療候選藥物。該公司的主要研究治療藥物 lenabasum 是一種合成的口服大麻素受體 2 型（CB2）激動劑，旨在通過利用身體的固有解決途徑來消除慢性炎症。Corbus 通過推進小分子化合物的臨牀前和臨牀研究，來滿足自身免疫和炎症疾病中的未滿足醫療需求。</p>
<p>lenabasum 目前正在進行針對瀰漫性皮膚系統性硬化症（dcSSc）的三期臨牀試驗，以及針對囊性纖維化相關炎症的二期研究。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Corbus Pharmaceuticals</li>
<li>Oklo 股票可能準備迎來另一次大幅上漲</li>
<li>D-Wave 的財報看起來疲軟，但投資者可能錯過了這一點</li>
<li>隨着 AI 反饋循環的加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Corbus Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Corbus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Corbus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corbus Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Corbus制藥控股

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

IBBQ

<p>Corbus 製藥控股公司（NASDAQ:CRBP）預計將在 2026 年第二季度報告每股收益（EPS）為（$1.24），根據 Lifesci Capital 的預測。該公司今年迄今股價上漲了 342%，全年每股收益的當前共識估計為（$4.78）。分析師的評級各不相同，其中有一項強烈買入、八項買入和兩項賣出評級。Corbus 最近報告的第一季度每股收益為（$1.23），超出預期，並且在 CRB-701 的註冊路徑上達成了 FDA 的對齊。該股票開盤價為$12.15，市值為 2.1554 億美元，評級共識為 “適度買入”</p>

<ul>
<li>Corbus Pharmaceuticals stock: An explosive 342% YTD surge</li>
</ul>
<div class="lb-trans"><ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
</div><p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 13th. Lifesci Capital analyst O. Mccammon forecasts that the biopharmaceutical company will post earnings per share of ($1.24) for the quarter. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.78) per share. Lifesci Capital also issued estimates for Corbus Pharmaceuticals' Q4 2026 earnings at ($1.51) EPS and FY2026 earnings at ($5.07) EPS.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - 免費報告) - Lifesci Capital 的股票研究人員在 2026 年第二季度的研究報告中發佈了對 Corbus Pharmaceuticals 的每股收益（EPS）預測，該報告於 5 月 13 日星期三發給客户和投資者。Lifesci Capital 分析師 O. Mccammon 預測該生物製藥公司本季度每股收益為（$1.24）。對 Corbus Pharmaceuticals 當前全年的共識預期為每股（$4.78）。Lifesci Capital 還發布了對 Corbus Pharmaceuticals 2026 年第四季度每股收益的預測為（$1.51）和 2026 財年的每股收益為（$5.07）。</p>
</div><p>Get <strong>Corbus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corbus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other analysts have also issued reports on CRBP. Wall Street Zen upgraded Corbus Pharmaceuticals from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a report on Saturday, April 25th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. Oppenheimer cut their price objective on Corbus Pharmaceuticals from $57.00 to $54.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday. Jefferies Financial Group cut their price objective on Corbus Pharmaceuticals from $36.00 to $33.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $45.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Corbus Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $42.33.</p>
<div class="lb-trans"><p>其他幾位分析師也對 CRBP 發佈了報告。華爾街禪在 4 月 25 日星期六的報告中將 Corbus Pharmaceuticals 的評級從 “強烈賣出” 上調至 “賣出”。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Corbus Pharmaceuticals 股票的 “賣出（d-）” 評級。Oppenheimer 在週三的報告中將 Corbus Pharmaceuticals 的目標價從 57.00 美元下調至 54.00 美元，並對該公司設定了 “跑贏大盤” 的評級。Jefferies Financial Group 在週二的報告中將 Corbus Pharmaceuticals 的目標價從 36.00 美元下調至 33.00 美元，並對該公司設定了 “買入” 評級。最後，Guggenheim 在週三的報告中重申了 “買入” 評級，並對 Corbus Pharmaceuticals 股票設定了 45.00 美元的目標價。一位股票研究分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，兩位分析師給予了賣出評級。根據 MarketBeat 的數據，Corbus Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 42.33 美元。</p>
</div><ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP 發出強烈買入信號</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on CRBP</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 CRBP 股票報告</strong></p>
</div><h2>Corbus Pharmaceuticals Trading Up 6.3%</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 股價上漲 6.3%</h2>
</div><p>Shares of NASDAQ:CRBP opened at $12.15 on Thursday. Corbus Pharmaceuticals has a 1 year low of $6.72 and a 1 year high of $20.56. The business has a fifty day simple moving average of $9.77 and a 200 day simple moving average of $9.66. The firm has a market cap of $215.54 million, a price-to-earnings ratio of -2.09 and a beta of 2.68.</p>
<div class="lb-trans"><p>NASDAQ:CRBP 的股票在週四開盤價為 12.15 美元。Corbus Pharmaceuticals 的一年低點為 6.72 美元，一年高點為 20.56 美元。該公司的 50 日簡單移動平均線為 9.77 美元，200 日簡單移動平均線為 9.66 美元。該公司的市值為 2.1554 億美元，市盈率為-2.09，貝塔值為 2.68。</p>
</div><p>Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.03.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals (NASDAQ:CRBP - 獲取免費報告) 最近在 5 月 12 日星期二公佈了季度財報。該生物製藥公司報告的每股收益為（$1.23），超出共識預期的（$1.26）0.03 美元。</p>
</div><h2>Hedge Funds Weigh In On Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Corbus Pharmaceuticals 的對沖基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. increased its stake in shares of Corbus Pharmaceuticals by 120.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 187,956 shares of the biopharmaceutical company's stock worth $1,530,000 after purchasing an additional 102,609 shares during the period. Aberdeen Group plc increased its stake in shares of Corbus Pharmaceuticals by 602.2% in the fourth quarter. Aberdeen Group plc now owns 1,321,750 shares of the biopharmaceutical company's stock worth $10,759,000 after purchasing an additional 1,133,519 shares during the period. HighVista Strategies LLC increased its stake in shares of Corbus Pharmaceuticals by 56.8% in the third quarter. HighVista Strategies LLC now owns 118,027 shares of the biopharmaceutical company's stock worth $1,493,000 after purchasing an additional 42,735 shares during the period. Virtu Financial LLC acquired a new stake in Corbus Pharmaceuticals during the fourth quarter worth about $88,000. Finally, Engineers Gate Manager LP acquired a new stake in Corbus Pharmaceuticals during the fourth quarter worth about $140,000. 64.64% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。Assenagon Asset Management S.A. 在第四季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 120.2%。Assenagon Asset Management S.A. 現在擁有 187,956 股該生物製藥公司的股票，價值 1,530,000 美元，在此期間又購買了 102,609 股。Aberdeen Group plc 在第四季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 602.2%。Aberdeen Group plc 現在擁有 1,321,750 股該生物製藥公司的股票，價值 10,759,000 美元，在此期間又購買了 1,133,519 股。HighVista Strategies LLC 在第三季度將其在 Corbus Pharmaceuticals 股票中的持股比例增加了 56.8%。HighVista Strategies LLC 現在擁有 118,027 股該生物製藥公司的股票，價值 1,493,000 美元，在此期間又購買了 42,735 股。Virtu Financial LLC 在第四季度收購了 Corbus Pharmaceuticals 的新股份，價值約 88,000 美元。最後，Engineers Gate Manager LP 在第四季度收購了 Corbus Pharmaceuticals 的新股份，價值約 140,000 美元。64.64% 的股票目前由機構投資者持有。</p>
</div><h2>Key Corbus Pharmaceuticals News</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 主要新聞</h2>
</div><p>Here are the key news stories impacting Corbus Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本週影響 Corbus Pharmaceuticals 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Corbus reported Q1 2026 EPS of <strong>($1.23)</strong>, beating consensus by $0.03, which suggests results were slightly better than expected for the quarter.</li>
<li>Positive Sentiment: The company said it reached broad FDA alignment on the registration path for <strong>CRB-701</strong> in head and neck squamous cell carcinoma and cervical cancer, a meaningful regulatory step toward a registrational study this summer.</li>
<li>Positive Sentiment: Corbus completed enrollment in the <strong>CANYON-1</strong> obesity study for <strong>CRB-913</strong>, with topline 16-week data expected this summer, adding a near-term catalyst.</li>
<li>Positive Sentiment: HC Wainwright and LifeSci Capital <strong>raised multiple earnings estimates</strong> across 2026-2030, reflecting improved expectations for the company’s long-term earnings trajectory.</li>
<li>Positive Sentiment: Several brokerages maintained constructive views, including <strong>Guggenheim’s buy rating</strong> and <strong>Oppenheimer’s outperform rating</strong>, signaling continued analyst confidence. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences</li>
<li>Neutral Sentiment: Corbus will present at upcoming investor conferences in New York, which may increase visibility but does not by itself change fundamentals. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences</li>
<li>Negative Sentiment: Q1 net loss widened to about <strong>$23.0 million</strong> and operating expenses increased, underscoring that Corbus remains a high-burn clinical-stage biotech with no profits yet.</li>
<li>Negative Sentiment: Oppenheimer <strong>cut its price target</strong> from $57 to $54, which is still bullish but may have tempered some enthusiasm.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Corbus 報告 2026 年第一季度每股收益為 <strong>($1.23)</strong>，超出共識預期 0.03 美元，表明本季度的結果略好於預期。</li>
<li>積極情緒：該公司表示已就 <strong>CRB-701</strong> 在頭頸部鱗狀細胞癌和宮頸癌的註冊路徑達成廣泛的 FDA 一致意見，這是朝着今年夏天進行註冊研究的重要監管步驟。</li>
<li>積極情緒：Corbus 完成了 <strong>CANYON-1</strong> 肥胖研究的入組，預計將在夏季發佈 16 周的頂線數據，增加了近期催化劑。</li>
<li>積極情緒：HC Wainwright 和 LifeSci Capital <strong>提高了 2026-2030 年的多項收益預期</strong>，反映出對公司長期收益軌跡的改善預期。</li>
<li>積極情緒：幾家券商維持了建設性的觀點，包括 <strong>Guggenheim 的買入評級</strong> 和 <strong>Oppenheimer 的跑贏大盤評級</strong>，顯示出分析師的持續信心。Corbus Pharmaceuticals 將參加即將舉行的投資者會議。</li>
<li>中性情緒：Corbus 將在紐約的即將舉行的投資者會議上進行演講，這可能會增加可見度，但本身並不會改變基本面。Corbus Pharmaceuticals 將參加即將舉行的投資者會議。</li>
<li>消極情緒：第一季度淨虧損擴大至約 <strong>2300 萬美元</strong>，運營費用增加，突顯出 Corbus 仍然是一家高燒錢的臨牀階段生物技術公司，尚未盈利。</li>
<li>消極情緒：Oppenheimer <strong>將其目標價</strong> 從 57 美元下調至 54 美元，儘管仍然看漲，但可能抑制了一些熱情。</li>
</ul>
</div><h2>About Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Corbus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc 是一家臨牀階段的生物製藥公司，致力於開發和商業化針對罕見、危及生命的炎症和纖維化疾病的治療候選藥物。該公司的主要研究治療藥物 lenabasum 是一種合成的口服大麻素受體 2 型（CB2）激動劑，旨在通過利用身體的固有解決途徑來消除慢性炎症。Corbus 通過推進小分子化合物的臨牀前和臨牀研究，來滿足自身免疫和炎症疾病中的未滿足醫療需求。</p>
</div><p>Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.</p>
<div class="lb-trans"><p>lenabasum 目前正在進行針對瀰漫性皮膚系統性硬化症（dcSSc）的三期臨牀試驗，以及針對囊性纖維化相關炎症的二期研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Corbus Pharmaceuticals</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Corbus Pharmaceuticals</li>
<li>Oklo 股票可能準備迎來另一次大幅上漲</li>
<li>D-Wave 的財報看起來疲軟，但投資者可能錯過了這一點</li>
<li>隨着 AI 反饋循環的加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRBP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corbus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Corbus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corbus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Corbus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Corbus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corbus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corbus Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

經紀商對 Corbus Pharma 第二季度收益的預測